Skip to main content

Table 1 Laboratory data

From: Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats

Parameters

Placebo (N = 13)

Ezetimibe (N = 10)

Xuezhikang (N = 10)

Xuezhikang + ezetimibe (N = 10)

Pitavstatin (N = 10)

Pitavstatin + ezetimibe (N = 10)

PCSK9 ng/ml

296.29 ± 112.95

664.76 ± 331.73*

461.20 ± 124.96*

482.86 ± 130.29*

626.16 ± 221.48*

901.35 ± 235.56*

TG mmol/l

0.76 ± 0.72

0.51 ± 0.17

1.38 ± 0.12

1.26 ± 0.29

0.44 ± 0.12

0.91 ± 0.18

TC mmol/l

2.13 ± 0.26

2.44 ± 0.40

2.25 ± 0.37

2.19 ± 0.40

2.50 ± 0.40

2.39 ± 0.33

HDL-C mmol/l

1.04 ± 0.29

1.31 ± 0.29

1.04 ± 0.29

0.94 ± 0.20

1.25 ± 0.27

1.22 ± 0.27

LDL-C mmol/l

0.53 ± 0.14

0.51 ± 0.15

0.45 ± 0.07

0.42 ± 0.04

0.64 ± 0.18

0.48 ± 0.09

  1. Data are expressed as means ± SD. * p < 0.05 versus placebo group. # p < 0.05 versus pitavastatin group. Δp < 0.05 versus Xuezhikang + ezetimibe group. PCSK9 = proprotein convertase subtilisin/kexin type 9; TG = triglycerides; TC = total cholesterol; HDL-C = high density lipoprotein cholesterol; LDL-C = low density lipoprotein cholesterol.